ArticleOpen forum infectious diseases2019
Impact of Obesity on Acyclovir-Induced Nephrotoxicity.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Updated antimicrobial dosing recommendations for obese patients.Antimicrobial agents and chemotherapy · 2024Pooled it
- Successful Treatment of Varicella Zoster Encephalitis in a Sarcopenic Obese Patient after Acyclovir-induced Acute Kidney Injury: The Necessity of Individualized Dosing.Internal medicine (Tokyo, Japan) · 2026Article
- Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.Open forum infectious diseases · 2026Review
- The Role of Metabolites in Acyclovir-Induced Neurotoxicity and Nephrotoxicity.Medicines (Basel, Switzerland) · 2026Review
- Assessing Renal Dysfunction Incidence Related to Intravenous Acyclovir Usage.Sultan Qaboos University medical journal · 2026Article
- Evaluation of Aciclovir-Induced Nephrotoxicity in Critically Ill Patients: A Propensity-Matched Cohort Study.Journal of clinical medicine · 2025Article
- Acyclovir Encephalopathy in HSV Encephalitis Elderly With Normal Renal Function.Case reports in neurological medicine · 2025Article
- Valacyclovir-associated acute kidney injury and encephalopathy in an elderly woman with normal kidney function: a case report.CEN case reports · 2023Article
- Fluid Stewardship of Maintenance Intravenous Fluids.Journal of pharmacy practice · 2022Review
- Incidence, patterns, risk factors and clinical outcomes of intravenous acyclovir induced nephrotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022Article
- Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years.European journal of pediatrics · 2021Article
- Frequency of and risk factors for carbapenem-resistantJournal of medical microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a major medical issue nationally, with rates continually increasing. In obese patients, minimal data exist for appropriate dosing of acyclovir to decrease the rates of nephrotoxicity. The purpose of this study was to determine the prevalence of and risk factors associated with acyclovir-induced nephrotoxicity.
methodsA retrospective case-control of patients who received intravenous acyclovir for >48 hours at the University of Mississippi Medical Center over a 4-year period were evaluated to elucidate the prevalence of acyclovir-induced nephrotoxicity. Additionally, risk factors for the development of nephrotoxicity, including the effect of obesity and dosing strategy, were assessed.
resultsOne hundred fifteen patients were included in the study. A total of 24 (21%) patients developed nephrotoxicity after acyclovir exposure and were in the Risk (9.6%), Injury (4.3%), and Failure (7%) categories, defined by the RIFLE criteria. Neither acyclovir dosage, fluid status, nor baseline characteristics, other than obesity, varied between those who developed nephrotoxicity vs those who did not. Independent predictors of nephrotoxicity were obesity (odds ratio [OR], 3.2; 95% confidence interval [CI], 1.19-8.67) and receipt of vancomycin (OR, 4.73; 95% CI, 1.57-14.25). No differences in vancomycin dosing or concentrations were observed between the patients who developed nephrotoxicity and those who did not.
conclusionsIn this study, nephrotoxicity occurred in 21% of patients receiving acyclovir. Concomitant vancomycin receipt and obesity led to higher rates of toxicity. Efforts should be made to target obese patients on acyclovir plus vancomycin and discontinue therapy in patients not warranting antiviral coverage to minimize chances of toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.